ImmunoPrecise Antibodies Ltd..
IPA.US | Research and experimental development on natural sciences and engineering
ImmunoPrecise Antibodies Ltd. is a biopharmaceutical company focused on the discovery and development of fully human antibodies. They offer a comprehensive suite of antibody discovery services, including hybridoma technology, B cell selection, and phage display, to generate antibodies against a wide...Show More
Better Health for All
0
No evidence available to assess ImmunoPrecise Antibodies Ltd. on Better Health for All.
Fair Money & Economic Opportunity
0
ImmunoPrecise Antibodies Ltd. (IPA.US) is a biopharmaceutical company focused on antibody discovery and development. Its core business activities do not involve lending, insuring, moving, or storing money for consumers, nor does it offer consumer credit products or financial services. Therefore, there is no evidence in the provided articles to assess the company against any of the KPIs related to 'Fair Money & Economic Opportunity', as these KPIs are designed for financial institutions. The company's informal educational outreach programs are for staff cybersecurity risks, not financial literacy for consumers.
1
The company's revenue allocation is geographic for its biopharmaceutical business, not related to financial service access points.
2
The use of proceeds from offerings is for R&D, capital expenditures, working capital, and general corporate purposes, which is standard business reinvestment and not specifically for community finance or profit-sharing with underserved communities.
3
Fair Pay & Worker Respect
0
No quantitative data relevant to the Fair Pay & Worker Respect metrics, such as living wage coverage, CEO-to-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage, was found in the provided articles. While CEO compensation was mentioned as CA$1.01M, median employee compensation was not provided, preventing the calculation of a pay ratio.
1
Fair Trade & Ethical Sourcing
0
No evidence available to assess ImmunoPrecise Antibodies Ltd. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-50
ImmunoPrecise Antibodies Ltd. has a Code of Ethics and Business Conduct, updated in September 2021, which outlines policies and procedures for reporting suspected violations to supervisors, the Chief Financial Officer, or the Audit Committee.
1
While a policy exists, there is no explicit mention of a dedicated hotline or evidence of independent investigation processes. The company's Code of Ethics and Business Conduct also includes policies on anti-bribery and anti-corruption, emphasizing compliance with applicable laws, including the U.S. Foreign Corrupt Practices Act and Canadian regulations.
2
A December 2023 Form 6-K filing explicitly states compliance with the FCPA as a representation and warranty.
3
However, there is no evidence of training frequency or effectiveness metrics for this policy. Independent legal opinions from Norton Rose Fulbright Canada LLP and Dorsey & Whitney LLP, along with an audit report from Grant Thornton LLP, were provided in relation to a public offering, indicating some third-party verification of compliance.
4
Kind to Animals
-30
ImmunoPrecise Antibodies (IPA) utilizes its AI-driven LENSai™ platform and integrated discovery tools as New Approach Methodologies (NAMs) to predict Anti-Drug-Antibody (ADA) risk for therapeutic proteins before animal studies or human trials, aiming to replace animal testing and shorten preclinical cycles.
1
The company supports the FDA's decision to phase out animal testing requirements for monoclonal antibodies and other pharmaceutical products and champions the transition toward more ethical methodologies.
2
IPA's investment in AI-driven platforms like LENSai™ aims to streamline preclinical workflows, reduce costs, and enhance ethical standards.
3
The company supports the FDA's shift towards NAMs, which includes a one-year pilot with select antibody developers to test NAMs, and scientists, patient advocates, and industry stakeholders can weigh in on the roadmap.
4
No War, No Weapons
0
No evidence available to assess ImmunoPrecise Antibodies Ltd. on No War, No Weapons.
Planet-Friendly Business
0
The company sources 65% of its total energy consumption from renewables.
1
It is ISO 14001:2015 certified with 98% compliance and has achieved 75% of the Green Laboratory Standard.
2
The company has set targets to reduce energy consumption by 15%, water usage by 20%, and chemical waste by 25% by 2025.
3
It invests $475,000 annually in climate adaptation and $1.2 million in research facility climate-proofing.
4
Digital protocol optimization has led to a 37% reduction in physical resource consumption, and computational modeling has decreased experimental waste by 42%.
5
Respect for Cultures & Communities
0
No evidence available to assess ImmunoPrecise Antibodies Ltd. on Respect for Cultures & Communities.
Safe & Smart Tech
0
The company's privacy policy outlines user rights for data access, correction, and deletion.
1
It states that data retention is based on need and legal requirements and references compliance with applicable data protection laws.
2
Zero Waste & Sustainable Products
0
No evidence available to assess ImmunoPrecise Antibodies Ltd. on Zero Waste & Sustainable Products.